Immunic, Inc. 2025 Annual Report (Amendment): Key Investor Insights

Overview

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company, has filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This amendment provides comprehensive Part III information, including details on directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and principal accountant fees. The company is headquartered at 1200 Avenue of the Americas, Suite 200, New York, NY 10036.

Key Points and Potentially Price-Sensitive Information

1. Reverse Stock Split Approved and Effective April 27, 2026

• Immunic shareholders approved a reverse stock split at a ratio of 1-for-10, effective April 27, 2026. While this amendment does not reflect the split unless specifically stated, it is a significant corporate action that could impact share price, investor perception, and liquidity.
• Rationale: Reverse splits are typically implemented to increase share price and maintain compliance with Nasdaq listing requirements, potentially making the stock more attractive to institutional investors.
• Outstanding Shares: As of April 16, 2026, there were 136,214,825 shares of common stock outstanding (pre-split).

2. Market Value and Securities Information

• Market Cap: Aggregate market value of common equity held by non-affiliates was \$83.1 million as of June 30, 2025. This valuation is important for investors tracking company size and institutional interest.
• Listing: Immunic’s common stock (\$0.0001 par value) trades on The Nasdaq Stock Market under the symbol “IMUX”.
• SEC Compliance: Immunic is not a well-known seasoned issuer, but is a non-accelerated filer and a smaller reporting company, which affects disclosure requirements.

3. Corporate Governance Highlights

• Active Board Oversight: The board held 13 meetings in 2025, with each director attending at least 75% of meetings.
• Board Committees:
  • Audit Committee: Oversees accounting and financial reporting, led by Mr. Phillips (audit committee financial expert). Responsible for engaging auditors, reviewing controls, and monitoring financial compliance.
  • Compensation Committee: Oversees executive compensation, reviews goals, performance, and recommends adjustments. Chaired by Mr. Congleton.
  • Nominating and Governance Committee: Oversees board membership, corporate governance, and cybersecurity policies. Charter documents for all committees are available on the company website.
• Code of Conduct & Insider Trading Policy: Written code applies to all directors, officers, and employees, prohibiting hedging and derivative trading in company securities.
• Clawback Policy: Adopted in 2023 per Nasdaq rules, requiring recovery of incentive-based compensation from executives in case of material accounting restatements, regardless of fault.
• Equity Compensation Policy: Board and committee do not time equity grants to take advantage of undisclosed information.

4. Executive Compensation: Details and Structure

• CEO Compensation (Dr. Daniel Vitt):
  • 2025 Total Compensation: \$2,311,272
    • Salary: \$610,000
    • Option Awards: \$2,160,474
    • Other Compensation: \$100,000 (housing allowance)
  • 2024 Total Compensation: \$2,311,272
• Other Named Executive Officers: Compensation details provided for COO/President Jason Tardio, Chief Medical Officer Dr. Andreas Muehler, Chief Financial Officer Glenn Whaley, and former Executive Chairman Dr. Duane Nash.
• Annual Bonuses: In February 2026, the board approved a 115% bonus payout for 2025 to several executives, paid in March and April 2026.
• Director Compensation:
  • Base retainer for non-employee directors: \$45,000; Chairman receives an additional \$35,000.
  • Committee Chairs receive additional fees (Audit: \$20,000; Nominating/Governance: \$10,000; Compensation: \$15,000).
  • Lead Independent Director receives \$10,000 annually.
  • Cash payments are made quarterly in arrears; directors are reimbursed for reasonable expenses.
  • Equity compensation is awarded to directors in addition to cash compensation.
• Outstanding Equity Awards: Detailed tables list stock options and appreciation rights for executives as of December 31, 2025, providing insight into potential dilution and alignment of interests.
• Potential Severance: Summaries of potential payments to executives upon termination (cash severance, accelerated equity, bonus) are provided, with amounts calculated using grant date fair values.

5. Governance and Shareholder Engagement

• Stockholder Recommendations: Shareholders can recommend board candidates in writing, including biographical data, qualifications, and evidence of ownership. The committee evaluates recommendations but is not obligated to act.
• Communications with Board: Shareholders or interested parties can communicate directly with non-management directors via the corporate secretary.
• Director Attendance: No formal policy, but directors are encouraged to attend annual meetings.
• Section 16(a) Compliance: All officers, directors, and >10% shareholders complied with required SEC filings in 2025.

Potential Share Price Impacts

• Reverse Stock Split: This is the most significant corporate action disclosed. Reverse splits can impact share price, liquidity, and investor perception.
• Executive Compensation and Bonuses: Substantial payouts and equity awards may affect investor sentiment regarding management incentives and alignment.
• Clawback Policy: Compliance with Nasdaq rules enhances governance but could affect executive compensation in the event of restatements.
• Market Cap: The relatively modest market cap may influence institutional interest and investment risk.
• Board and Committee Activity: Strong governance and compliance may positively influence confidence, although no material adverse events are disclosed.

Conclusion

Immunic, Inc.’s amended annual report contains several important disclosures for investors, most notably the approval and execution of a reverse stock split, robust executive compensation, and strengthened governance policies. The reverse stock split is particularly price-sensitive, as it may significantly impact share price and liquidity. Investors should closely monitor upcoming corporate actions and subsequent SEC filings for further developments.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. All information is based on the company’s SEC filings and is subject to change.

View IMMUNIC, INC. Historical chart here